Napredovali MTC - izziv za zdravljenje

Izpis gradiva
A+ | A- | | SLO | ENG

Naslov:	Napredovali MTC - izziv za zdravljenje
Avtorji:	ID Bergant, Damijan (Avtor)
Datoteke:	PDF - Predstavitvena datoteka, prenos (136,71 KB) MD5: 792A7687154328AA9D2F4E6351756A00 PID: 20.500.12556/dirros/7f7118f6-604b-4a03-8234-7b57542c33d2
Jezik:	Slovenski jezik
Tipologija:	1.04 - Strokovni članek
Organizacija:	OI - Onkološki inštitut Ljubljana
Status publikacije:	Objavljeno
Verzija publikacije:	Objavljena publikacija
Leto izida:	2009
Št. strani:	str. 60-63
Številčenje:	Letn. 13, št. 1
PID:	20.500.12556/DiRROS-8596
UDK:	616-006
ISSN pri članku:	1408-1741
URN:	URN:NBN:SI:doc-B5E8Q06V
COBISS.SI-ID:	25707993
Avtorske pravice:	by Authors
Opomba:	BSDOCID145268;
Datum objave v DiRROS:	31.08.2018
Število ogledov:	3126
Število prenosov:	704
Metapodatki:
:	Kopiraj citat

Objavi na:

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Licenca:	CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna

Povezava:	http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:	To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:	31.08.2018

Jezik:	Angleški jezik
Naslov:	Advanced Medullary Thyroid Carcinoma – a Challenge for Multimodal Treatment (Case Presentation)
Povzetek:	Medullary thyroid cancer is a rare, neuroendocrine, tumor. It arises from parafollicular or C-cells with the ability to produce and secrete different bioactive substances like calcitonin (TC) and CEA. MTC occurs as a sporadic tumor or in hereditary settings MEN 2A, MEN 2B and FMCT. Germ line point mutations in RET proto-oncogene are responsible for tumor rise and inheritance of settings. RET mutations diagnostics in MTC patients and their first degree relatives form the basis of genetic screening. Biological behavior of MTC shows great clinical variability. Surgery is still the treatment of choice for MTC while teleradiotherapy, chemotherapy and radioimmunotherapy are indicated in advanced disease. Molecularly targeted treatments are now part of clinical studies with some promising results. Status at admission is still the most important prognostic factor. Diagnostics, treatment - including molecularly targeted treatment and follow-up of 29-years-old patient with respiratory distress due to the advanced MTC is represented. In this case, inhibitors of receptor tyrosine kinases were used for the first time as a part of multimodal treatment of MTC at the Institute of Oncology (OI).

niGradiv

Nazaj